KRAS and cancer: In patients with different types of advanced cancers, including ovarian, the simultaneous presence of mutations in PIK3CA (especially p.H1047R) and KRAS in codons 12 or 13, has been associated with resistance to therapy with PIK3CA/AKT/mTOR inhibitors, although data were not completely confirmed in multivariate models [44].